Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Dihydroergotamine Mesylate Nasal
Generic Name
Dihydroergotamine Mesylate Nasal
Active Ingredient
DihydroergotamineCategory
Other
Salt Form
Mesylate
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 4 mg/mL | SPRAY, METERED | NASAL | 69097-503 |
Detailed information about Dihydroergotamine Mesylate Nasal
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Dihydroergotamine Mesylate Nasal, you must consult a qualified healthcare professional.
Dihydroergotamine is a potent ergot alkaloid derivative used for the acute treatment of migraine and cluster headaches. It works by constricting intracranial blood vessels and inhibiting neurogenic inflammation through selective serotonin receptor agonism.
The dosage of dihydroergotamine varies significantly based on the route of administration. Healthcare providers emphasize that the medication should be administered at the first sign of a migraine headache for maximum efficacy.
The safety and effectiveness of dihydroergotamine in pediatric patients (under the age of 18) have not been established by the FDA. While some pediatric neurologists may prescribe it off-label for adolescents with severe refractory migraines, this is done under specialized care. Most clinical guidelines suggest avoiding ergot alkaloids in children due to the risk of vascular side effects.
Dihydroergotamine is contraindicated (should not be used) in patients with severe renal failure. In patients with mild to moderate kidney issues, healthcare providers use extreme caution as the drug's clearance may be affected.
Because DHE is primarily metabolized by the liver, it is contraindicated in patients with severe hepatic impairment. Liver dysfunction can lead to dangerously high levels of the drug in the blood, increasing the risk of ergotism (vasospasm).
Clinical studies of DHE did not include sufficient numbers of subjects aged 65 and over. In general, ergot alkaloids are avoided in the elderly due to the higher prevalence of underlying cardiovascular disease, which increases the risk of heart attack or stroke when using vasoconstrictors.
Since dihydroergotamine is an 'as-needed' (PRN) medication for acute attacks, there is no regular dosing schedule. However, if you forget to take it at the start of an attack, you can take it as soon as you remember, provided you do not exceed the daily or weekly limits. Do not 'double up' doses to make up for a late start.
An overdose of dihydroergotamine is a medical emergency. Symptoms include severe numbness or tingling in the fingers and toes, extreme muscle pain in the arms and legs, chest pain, rapid or weak pulse, confusion, and seizures. In cases of suspected overdose, contact emergency services (911) or a poison control center immediately. Treatment usually involves supportive care and vasodilators to restore blood flow to affected limbs.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without medical guidance. Overusing this medication can lead to 'rebound' headaches.
Most patients tolerate dihydroergotamine well when used as directed, but because it affects multiple receptor systems, side effects are common. These are typically transient (temporary) and resolve as the drug leaves the system.
> Warning: Stop taking Dihydroergotamine and call your doctor or emergency services immediately if you experience any of the following symptoms. These may indicate a life-threatening vascular event.
While dihydroergotamine is not meant for daily use, chronic overuse (taking it more than 2-3 days per week) can lead to specific long-term complications:
Dihydroergotamine carries a FDA Black Box Warning—the most serious level of warning—regarding its use with certain other medications.
Warning Text Summary: Serious and/or life-threatening peripheral ischemia (reduced blood flow to limbs) has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors, including protease inhibitors (for HIV) and macrolide antibiotics (like erythromycin). Because these inhibitors block the breakdown of DHE, the drug reaches toxic levels in the blood, causing extreme and prolonged vasoconstriction. This can lead to gangrene and the need for amputation. Use of these medications together is strictly contraindicated.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Monitoring your response to the first few doses is essential for long-term safety.
Dihydroergotamine is a powerful medication that requires careful screening by a healthcare professional. It is not a general-purpose painkiller and should never be shared with others. Patients with a history of heart disease, circulation problems, or uncontrolled high blood pressure must not use this drug. Because it causes blood vessels to narrow throughout the body, it can potentially affect any organ system that relies on robust blood flow.
Coadministration with Potent CYP3A4 Inhibitors: As noted in the side effects section, DHE must never be used with drugs that significantly inhibit the CYP3A4 enzyme. This includes certain anti-fungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin), and many HIV/HCV protease inhibitors (ritonavir, nelfinavir). The resulting 'ergot toxicity' can cause catastrophic loss of blood flow to the extremities or brain.
For patients using dihydroergotamine occasionally, routine lab work is rarely required. However, for those using it more frequently, healthcare providers may monitor:
Dihydroergotamine can cause dizziness, sedation (sleepiness), and visual disturbances. You should not drive a car, operate heavy machinery, or engage in hazardous activities until you are certain how the medication affects you. The fatigue following a migraine attack (the 'migraine hangover') combined with the drug's side effects can significantly impair reaction times.
Alcohol is a known migraine trigger for many people. Furthermore, alcohol acts as a vasodilator (widens blood vessels), which can counteract the therapeutic effects of DHE. Combining alcohol with DHE may also increase the risk of dizziness and nausea. It is generally advised to avoid alcohol during and immediately after a migraine attack.
There is no physical 'withdrawal' from DHE in the traditional sense; however, if you have been overusing the drug (taking it more than twice a week), stopping it may cause a temporary increase in headache frequency (rebound). In these cases, a doctor may suggest a 'taper' or provide alternative 'bridge' medications to help you transition off the drug safely.
> Important: Discuss all your medical conditions, especially any history of heart, liver, or kidney disease, with your healthcare provider before starting Dihydroergotamine.
Certain drug combinations are so dangerous with dihydroergotamine that they are strictly forbidden:
Dihydroergotamine is not known to significantly interfere with most common laboratory tests (such as basic metabolic panels or complete blood counts). However, always inform the lab technician and your doctor that you are using this medication.
If an interaction is suspected, the management strategy usually involves:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.
In certain scenarios, the risks of dihydroergotamine far outweigh any potential benefits. It must NEVER be used in the following cases:
Relative contraindications require a careful risk-benefit analysis by a specialist:
Patients who have had a severe allergic reaction (anaphylaxis) to ergotamine tartrate, methylergonovine, or any other ergot alkaloid should not use dihydroergotamine. While the chemical structures differ slightly, the risk of cross-reactivity is significant enough to warrant avoidance.
> Important: Your healthcare provider will evaluate your complete medical history, including your cardiovascular risk profile, before prescribing Dihydroergotamine.
FDA Pregnancy Category X (for most formulations): Dihydroergotamine is strictly contraindicated during pregnancy. Clinical data and pharmacological principles indicate that DHE can cause fetal harm. Its oxytocic effects can induce uterine contractions, which may lead to spontaneous abortion or impaired placental blood flow, resulting in fetal growth restriction. If you become pregnant while using this medication, stop use immediately and consult your obstetrician. It is not used in fertility treatments and may actually interfere with the uterine environment necessary for implantation.
Ergot alkaloids, including dihydroergotamine, are known to be excreted in human breast milk. There are two primary concerns:
Most healthcare providers recommend that mothers avoid breastfeeding for at least 24 hours after using a dose of DHE to minimize infant exposure.
Dihydroergotamine is not FDA-approved for use in children or adolescents under the age of 18. The primary concern is the potential for increased sensitivity to the vasoconstrictive effects of the drug. While some specialist headache centers use DHE for refractory pediatric migraines, this is done under high-acuity monitoring. There is no data on how DHE might affect growth or development in children.
Use in patients over age 65 is generally discouraged. The elderly are more likely to have decreased hepatic or renal function, which can lead to drug accumulation. More importantly, the prevalence of coronary artery disease and peripheral vascular disease is much higher in this population. The risk of a cardiovascular event (heart attack or stroke) following the administration of a potent vasoconstrictor like DHE is significantly elevated in older adults.
In patients with mild to moderate renal impairment, the elimination of DHE may be slowed. While the drug is primarily cleared by the liver, the kidneys handle approximately 10% of the dose. In severe renal failure, the drug is contraindicated because the altered metabolic state of the body can increase the risk of systemic vasospasm.
As the liver is the primary site of metabolism for dihydroergotamine, hepatic impairment significantly increases the drug's half-life and peak plasma concentrations. It is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For those with mild to moderate impairment, dose reductions and frequent monitoring for signs of ergotism are required.
> Important: Special populations require individualized medical assessment. Always disclose your full health status to your medical team.
Dihydroergotamine (DHE) is a complex ligand that interacts with a variety of receptors. Its primary therapeutic effect in migraines is attributed to its high affinity for 5-HT1B and 5-HT1D serotonin receptors.
| Parameter | Value |
|---|---|
| Bioavailability | ~32% (Nasal), ~100% (Injection), <1% (Oral) |
| Protein Binding | 93% |
| Half-life | 9 - 10 hours (Terminal) |
| Tmax | 0.5 - 1 hour (Nasal) |
| Metabolism | Hepatic (Primarily CYP3A4) |
| Excretion | Fecal (~90%), Renal (~10%) |
Dihydroergotamine is classified as an Ergot Alkaloid Derivative. It is part of the 'Abortive Migraine Therapy' group. Related medications include Ergotamine Tartrate (Cafergot) and Methylergonovine (Methergine), though the latter is used primarily in obstetrics rather than for headaches.
Common questions about Dihydroergotamine Mesylate Nasal
Dihydroergotamine is primarily used for the acute treatment of migraine attacks, with or without aura, and cluster headache episodes in adults. It is an 'abortive' therapy, meaning it is designed to stop a headache that has already begun rather than preventing future ones. Healthcare providers often prescribe it for patients who do not find relief from standard treatments like triptans or NSAIDs. It is particularly effective for long-lasting migraines or 'status migrainosus.' Because of its potent effects, it is usually reserved for moderate to severe attacks.
The most frequently reported side effects include nasal irritation, congestion, and a bitter taste in the mouth when using the nasal spray. Nausea and vomiting are also very common across all forms of the drug because it interacts with dopamine receptors in the brain. Some patients may experience dizziness, drowsiness, or minor muscle aches in the legs. While these are usually mild, any sensation of numbness or coldness in the fingers and toes should be reported to a doctor immediately. Most side effects are temporary and resolve as the medication is cleared from the body.
It is generally advised to avoid alcohol while using dihydroergotamine for several reasons. First, alcohol is a common trigger for migraines and can make the current attack worse or more difficult to treat. Second, alcohol is a vasodilator, which works against the vasoconstricting action of the medication. Finally, combining the two can increase the severity of side effects like nausea, dizziness, and drowsiness. To ensure the medication works effectively and safely, patients should abstain from alcohol during and immediately after a migraine.
No, dihydroergotamine is strictly contraindicated during pregnancy and is classified as FDA Pregnancy Category X. It has oxytocic properties that can cause the uterus to contract, which may lead to miscarriage or preterm labor. Additionally, it can constrict blood vessels in the placenta, potentially harming the developing fetus. Women of childbearing age should use effective contraception while being treated with DHE. If you discover you are pregnant, you must stop using the medication and contact your healthcare provider immediately to discuss safer alternatives for migraine management.
The onset of action depends on how the drug is administered. When given intravenously (IV) in a clinical setting, the effects are almost immediate. Intramuscular (IM) or subcutaneous (SC) injections typically begin to work within 15 to 30 minutes. The nasal spray formulations (like Migranal or Trudhesa) generally take slightly longer, with most patients noticing significant relief within 30 to 60 minutes. Because migraines can progress quickly, the medication is most effective when taken at the very first sign of a headache.
Since dihydroergotamine is taken only as needed for individual migraine attacks, there is no risk of 'withdrawal' in the traditional sense if you stop using it. However, if you have been overusing the medication (taking it more than 2 or 3 days per week), you may experience 'medication overuse headaches.' In this scenario, stopping the drug can cause a temporary spike in headache frequency and intensity. If you find yourself needing DHE frequently, consult your doctor about starting a daily preventative medication instead.
Because dihydroergotamine is an 'as-needed' medication for acute attacks, there is no such thing as a 'missed dose' in a daily schedule. You simply take the medication when a migraine begins. However, if you forget to take it at the start of an attack, you can still take it later, though it may be less effective. Always ensure you follow the specific timing rules for repeat doses (e.g., waiting 15 minutes between nasal sprays) and never exceed the maximum daily or weekly limits prescribed by your doctor.
There is no clinical evidence to suggest that dihydroergotamine causes weight gain. Unlike some preventative migraine medications (such as certain antidepressants or anti-seizure drugs) which are taken daily and can affect metabolism or appetite, DHE is used only intermittently for acute attacks. Because it is not a chronic, daily medication, it does not have the opportunity to influence long-term body weight. If you are experiencing weight changes, they are likely due to other medications or lifestyle factors and should be discussed with your physician.
Dihydroergotamine has many serious drug interactions and must be used with caution. It should never be taken within 24 hours of other ergot-type drugs or triptans (like sumatriptan), as this can cause dangerous levels of blood vessel constriction. It also has a 'Black Box Warning' against use with potent CYP3A4 inhibitors like certain antibiotics and HIV medications. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking to avoid potentially life-threatening interactions.
Yes, dihydroergotamine mesylate is available as a generic in both injectable and nasal spray forms. The generic versions are bioequivalent to the brand-name versions like D.H.E. 45 and Migranal, meaning they contain the same active ingredient and work the same way in the body. Generic options are typically more cost-effective for patients. However, some newer delivery systems, such as the Trudhesa nasal spray which uses a specific POD device, may only be available as a brand-name product for several years until its patent expires.
Other drugs with the same active ingredient (Dihydroergotamine)